-transparent.png){kind=logo}
A phase II trial of gallium nitrate (250-300 mg/m2/day for 7 consecutive days) was conducted in patients with metastatic melanoma. Therapy was well-tolerated, but only one of 31 evaluable patients experienced a partial regression. Further evaluation of gallium nitrate at this dose and schedule is not warranted in patients with malignant melanoma.
Related Publications
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
January 1984,
Anticancer research,
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
June 2002,
American journal of clinical oncology,
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
April 1984,
Cancer treatment reports,
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
February 1987,
Cancer treatment reports,
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
November 1993,
Investigational new drugs,
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
February 1987,
European journal of cancer & clinical oncology,
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
February 1983,
European journal of cancer & clinical oncology,
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
January 1999,
Urologia internationalis,
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
November 1987,
European journal of cancer & clinical oncology,
E S Casper, and
G F Stanton, and
P P Sordillo, and
R Parente, and
R A Michaelson, and
V Vinceguerra
January 1980,
Cancer treatment reports,
